PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Indirect Network Meta-Analysis Ranks Cardiorenal Drugs in Diabetic CKD

GLP-1 receptor agonistsSGLT2 inhibitorsnon-steroidal mineralocorticoid receptor antagonistsfinerenonesemaglutidedapagliflozincanagliflozinempagliflozintype 2 diabeteschronic kidney diseasecardiorenal outcomesnetwork meta-analysisFLOW trial Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors show promise for renal outcomes in T2D-CKD.

The study evaluates potential cardiovascular and renal benefits and safety profiles of GLP-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter 2 inhibitors (SGLT2is), and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in patients with type 2 diabetes and chronic kidney disease (T2D-CKD). SGLT2is showed greater reductions in major kidney outcomes and hospitalization for heart failure compared to nsMRAs and GLP-1RAs, while GLP-1RAs were more favorable for cardiovascular death. Indirect comparisons suggest SGLT2is may offer better renal benefits, but confidence in evidence is low to moderate. Direct comparative trials are needed for conclusive guidance. SGLT2 inhibitors may provide superior renal outcomes in T2D-CKD, yet direct head-to-head trials are needed.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chen H, Wu X, Yuan M, Ren F, Liu T, Yang L, An X, Zhan Y

Citation: Chen H, Wu X, Yuan M, et al. Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis. Frontiers in endocrinology. 2026;17:1937754. doi:10.3389/fendo.2026.1937754

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.